http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_12cde303a87c2cf3d8ce72a80f2e8530
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Isin |
| name | Emre M. Isin Emre M Isin |
| given-name | Emre M Emre M. |
| organization-name | Les Laboratoires Servier SAS Recherche and Developpement, DMPK, Translational Medicine, Servier, France Department of Chemistry, Virginia Tech, Blacksburg, Virginia 24061 DMPK Innovative Medicine, AstraZeneca, Mölndal, 431 83, Sweden CVGI iMed DMPK, ADME Section‡DMPK iMed, Screening & Profiling, Isotope Chemistry, and §DMPK iMed, Centre of Excellence, AstraZeneca R&D, Mölndal, SE 431 83 Sweden Departments of Biochemistry and Medicine and the Center for Structural Biology, and Center in Molecular Toxicology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146 DMPK Design and Biotransformation, CVMD iMed DMPK, AstraZeneca R&D Mölndal, Sweden, Pepparedsleden 1, SE-431 83, Mölndal, Sweden Contribution from the Department of DMPK and Bioanalytical Chemistry, AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden, and the Department of Chemistry, Virginia Tech, Blacksburg, Virginia 24061-0212 Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Pepparedsleden 1, Mölndal SE-431 83, Sweden CVMD iMed DMPK, ‡Drug Safety & Metabolism, AstraZeneca R&D Mölndal, 431 83 Mölndal, Sweden DMPK, Cardiovascular & Metabolic Diseases iMed, AstraZeneca R&D, 431 83 Mölndal, Sweden CVGI Innovative Medicine DMPK, AstraZeneca, Mölndal 431 83, Sweden Cardiovascular, Renal and Metabolism, Innovative Medicines and Early Development Biotech Unit AstraZeneca Gothenburg Sweden |
Incoming Links
Total number of triples: 43.